Logo image of ALXO

ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Fundamental Analysis

NASDAQ:ALXO - Nasdaq - US00166B1052 - Common Stock - Currency: USD

0.579  +0.05 (+10.29%)

After market: 0.59 +0.01 (+1.9%)

Fundamental Rating

1

Overall ALXO gets a fundamental rating of 1 out of 10. We evaluated ALXO against 559 industry peers in the Biotechnology industry. ALXO has a bad profitability rating. Also its financial health evaluation is rather negative. ALXO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALXO had negative earnings in the past year.
ALXO had a negative operating cash flow in the past year.
ALXO had negative earnings in each of the past 5 years.
ALXO had a negative operating cash flow in each of the past 5 years.
ALXO Yearly Net Income VS EBIT VS OCF VS FCFALXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -107.44%, ALXO is doing worse than 78.35% of the companies in the same industry.
ALXO has a worse Return On Equity (-147.73%) than 62.43% of its industry peers.
Industry RankSector Rank
ROA -107.44%
ROE -147.73%
ROIC N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ALXO Yearly ROA, ROE, ROICALXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALXO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALXO Yearly Profit, Operating, Gross MarginsALXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for ALXO has been increased compared to 1 year ago.
The number of shares outstanding for ALXO has been increased compared to 5 years ago.
The debt/assets ratio for ALXO is higher compared to a year ago.
ALXO Yearly Shares OutstandingALXO Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALXO Yearly Total Debt VS Total AssetsALXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ALXO has an Altman-Z score of -9.91. This is a bad value and indicates that ALXO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.91, ALXO is doing worse than 73.35% of the companies in the same industry.
A Debt/Equity ratio of 0.11 indicates that ALXO is not too dependend on debt financing.
The Debt to Equity ratio of ALXO (0.11) is worse than 66.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -9.91
ROIC/WACCN/A
WACCN/A
ALXO Yearly LT Debt VS Equity VS FCFALXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ALXO has a Current Ratio of 5.42. This indicates that ALXO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.42, ALXO is in line with its industry, outperforming 56.35% of the companies in the same industry.
ALXO has a Quick Ratio of 5.42. This indicates that ALXO is financially healthy and has no problem in meeting its short term obligations.
ALXO has a Quick ratio (5.42) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.42
Quick Ratio 5.42
ALXO Yearly Current Assets VS Current LiabilitesALXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

ALXO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.60%, which is quite impressive.
EPS 1Y (TTM)33.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.65% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.56%
EPS Next 2Y21.52%
EPS Next 3Y16.53%
EPS Next 5Y23.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALXO Yearly Revenue VS EstimatesALXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2027 2028 2029 2030 2031 2032 100M 200M 300M
ALXO Yearly EPS VS EstimatesALXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALXO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALXO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALXO Price Earnings VS Forward Price EarningsALXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALXO Per share dataALXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

ALXO's earnings are expected to grow with 16.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.52%
EPS Next 3Y16.53%

More info and screens

0

5. Dividend

5.1 Amount

ALXO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALX ONCOLOGY HOLDINGS INC

NASDAQ:ALXO (6/6/2025, 8:00:00 PM)

After market: 0.59 +0.01 (+1.9%)

0.579

+0.05 (+10.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06/amc
Inst Owners72.03%
Inst Owner Change-15.17%
Ins Owners1.22%
Ins Owner Change1.74%
Market Cap30.94M
Analysts81.67
Price Target2.65 (357.69%)
Short Float %13.73%
Short Ratio11.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.51%
Min EPS beat(2)-22.55%
Max EPS beat(2)19.52%
EPS beat(4)3
Avg EPS beat(4)6.93%
Min EPS beat(4)-22.55%
Max EPS beat(4)27.1%
EPS beat(8)5
Avg EPS beat(8)0.36%
EPS beat(12)7
Avg EPS beat(12)-0.55%
EPS beat(16)9
Avg EPS beat(16)-1.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-43.97%
PT rev (3m)-35.54%
EPS NQ rev (1m)-3.69%
EPS NQ rev (3m)30.98%
EPS NY rev (1m)2.57%
EPS NY rev (3m)33.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-2.47
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS0
BVpS1.65
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -107.44%
ROE -147.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.92%
ROA(5y)-46.28%
ROE(3y)-83.34%
ROE(5y)-56.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.42
Quick Ratio 5.42
Altman-Z -9.91
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)207.83%
Cap/Depr(5y)2095.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.31%
EPS Next Y34.56%
EPS Next 2Y21.52%
EPS Next 3Y16.53%
EPS Next 5Y23.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.81%
EBIT Next 3Y17.54%
EBIT Next 5YN/A
FCF growth 1Y-11.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.11%
OCF growth 3YN/A
OCF growth 5YN/A